{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137044753479552.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/dom.12936"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12936"}},{"identifier":{"@type":"URI","@value":"https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.12936"}}],"dc:title":[{"@value":"The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                    <jats:title>Aims</jats:title>\n                    <jats:p>Albuminuria reduction is essential for renal and cardiovascular protection. We characterized the efficacy of dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on albuminuria. Secondly, we assessed whether the albuminuria‐lowering effect varies among patients, and whether this variability in response is reproducible.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods</jats:title>\n                    <jats:p>\n                      A double‐blind, randomized, placebo controlled crossover trial was conducted. Patients with type 2 diabetes and albumin:creatinine ratio > 100 mg/g on a stable dose of an angiotensin‐converting enzyme inhibitor (\n                      <jats:styled-content style=\"fixed-case\">ACEi</jats:styled-content>\n                      ) or angiotensin receptor blocker (\n                      <jats:styled-content style=\"fixed-case\">ARB</jats:styled-content>\n                      ) were enrolled. Patients were assigned to 6‐week treatment periods with dapagliflozin 10 mg/d or placebo in random order, separated by 6‐weeks wash‐out periods. After the 2 treatment periods, half of the patients were re‐exposed for 6 weeks to dapagliflozin 10 mg/d. Primary outcome was change in 24‐hour urinary albumin excretion rate (24 h\n                      <jats:styled-content style=\"fixed-case\">UAE</jats:styled-content>\n                      ). To assess reproducibility in individual albuminuria response, responses from the first and second exposure to dapagliflozin were correlated.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      A total of 33 patients (age, 61 years; female gender, 24.2%; median 24 h\n                      <jats:styled-content style=\"fixed-case\">UAE</jats:styled-content>\n                      , 470 mg/24 h) completed the study. Dapagliflozin, as compared to placebo, reduced 24 h\n                      <jats:styled-content style=\"fixed-case\">UAE</jats:styled-content>\n                      by 36.2% (95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      , 22.9‐47.2;\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P</jats:styled-content>\n                      </jats:italic>\n                       < .001). Systolic blood pressure fell by 5.2\n                      <jats:styled-content style=\"fixed-case\">mm Hg</jats:styled-content>\n                      (95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      , 0.5‐10.0) and\n                      <jats:styled-content style=\"fixed-case\">eGFR</jats:styled-content>\n                      by 5.3 (95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      , 2.7‐8.0). All effects were reversible directly after treatment discontinuation. In a subgroup of 15 patients who were exposed twice to dapagliflozin, 24 h\n                      <jats:styled-content style=\"fixed-case\">UAE</jats:styled-content>\n                      responses showed a large variation among individuals: first exposure (range, −76% to +52%) and second exposure (−90% to +95%) and first and second individual response were significantly correlated (r = 0.69 [95%\n                      <jats:styled-content style=\"fixed-case\">CI</jats:styled-content>\n                      , 0.27‐0.89];\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P</jats:styled-content>\n                      </jats:italic>\n                       < .004).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion</jats:title>\n                    <jats:p>\n                      Dapagliflozin significantly reduces albuminuria when given as adjunct to\n                      <jats:styled-content style=\"fixed-case\">ACEi</jats:styled-content>\n                      or\n                      <jats:styled-content style=\"fixed-case\">ARB</jats:styled-content>\n                      . The albuminuria response to dapagliflozin markedly varies among patients. This variation is not a random phenomenon, but is reproducible upon re‐exposure. These data support personalized therapy approaches to optimize diabetic kidney disease.\n                    </jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137044753479682","@type":"Researcher","foaf:name":[{"@value":"Sergei I. Petrykiv"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044753479680","@type":"Researcher","foaf:name":[{"@value":"Gozewijn D. Laverman"}],"jpcoar:affiliationName":[{"@value":"Department of Nephrology Ziekenhuisgroep Twente  Almelo and Hengelo the Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044753479552","@type":"Researcher","foaf:name":[{"@value":"Dick de Zeeuw"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044753479681","@type":"Researcher","foaf:name":[{"@value":"Hiddo J. L. Heerspink"}],"jpcoar:affiliationName":[{"@value":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen the Netherlands"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14628902"},{"@type":"EISSN","@value":"14631326"}],"prism:publicationName":[{"@value":"Diabetes, Obesity and Metabolism"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2017-06-08","prism:volume":"19","prism:number":"10","prism:startingPage":"1363","prism:endingPage":"1370"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fdom.12936"},{"@id":"https://dom-pubs.pericles-prod.literatumonline.com/doi/pdf/10.1111/dom.12936"}],"createdAt":"2017-03-14","modifiedAt":"2025-10-31","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360283695654611200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710481032960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360849946813946624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861707377018112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of sodium‐glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/dom.12936"},{"@type":"CROSSREF","@value":"10.3390/ijms18051083_references_DOI_K0RMIFqXY5V4HPy6LYICCn1Rkzh"},{"@type":"CROSSREF","@value":"10.1111/dom.13648_references_DOI_K0RMIFqXY5V4HPy6LYICCn1Rkzh"},{"@type":"CROSSREF","@value":"10.1186/s12933-019-0912-3_references_DOI_K0RMIFqXY5V4HPy6LYICCn1Rkzh"},{"@type":"CROSSREF","@value":"10.1111/dom.14976_references_DOI_K0RMIFqXY5V4HPy6LYICCn1Rkzh"}]}